Medscape:2012年美国神经科医生调查报告

2012-04-10 陈蓉 脉通

       近期,Medscape对美国医生的生活方式进行了一项大规模的调查,包括幸福感、娱乐方式、身体状况和财务状况。一起看看来自大洋彼岸的美国医生,他们给自己打多少分。 以下是神经科医生的相关调查结果:        当被问及工作之外的生活幸福度时,神经医生幸福感得分为3.88(满分5.00),比

       近期,Medscape对美国医生的生活方式进行了一项大规模的调查,包括幸福感、娱乐方式、身体状况和财务状况。一起看看来自大洋彼岸的美国医生,他们给自己打多少分。
以下是神经科医生的相关调查结果:
       当被问及工作之外的生活幸福度时,神经医生幸福感得分为3.88(满分5.00),比整体医生的平均分3.96要低。神经科医生的健康水平与其他医生基本一致。约有32%超重,有4.8%肥胖。面对绝症时,神经科医生可能和其他人一样,不知道如何处理。63%说他们重视生活质量胜过生命长短,但是具有年龄差异。31~40岁的人群中,18%的人说会积极治疗,61岁的人中只有6.7%的人说会积极治疗。


详细调查结果

1、工作之外的生活幸福吗?
       所有医生的平均得分为3.96,神经科医生得分较低,为3.88分,与肠胃科和内科医生并列最后。
2、业余爱好是什么?
       最爱好的是reading,其次是运动,旅游,文化活动,食品和美酒,网上冲浪。一些更有趣的回答包括,钓鱼,耕种,收集和赛老爷车。玩电玩等也榜上有名。
3、喜欢在哪里参加志愿者活动?
       许多神经科医生说,他们在子女的学校做志愿活动,另有一些回答在协助保护动物,参加社区教育,甚至在纽约时装周做志愿服务。
4、政治倾向性?
       23%的神经科医生定义自己为社会和财政保守派;25%的人认为自己在这两个区域为自由主义者,比普通大众的比例要高。数据被进一步细分后,有66%说他们是财政保守,超过2/3的人是社会自由主义者。
5、去哪度假?
       57%的神经科医生报告,每年会花2~4周度假,12%的会花4周或以上,近30%的每年花在度假的时间不到2周。因为收入较高,首选是外国旅行,其次是海滩住宿,度假村,游艇等。
6、结婚和单身的比例?
     这项调查的神经科医生中,68%已婚(初婚),比例与总体水平相当;离婚率(2.6%)比总体医生水平比例(4.6%)低很多。
7、婚姻状况是否影响幸福水平?
       据调查,得分最高的神经科医生是那些有伴侣的人,不管是否结婚,是第一次还是第二次婚姻。
 8、怎么评估自身健康的?
       用1~5分来评估健康,5分是最好。认为自身健康的医生排名是:皮肤科、整形外科、内分泌科、骨科和心脏病学。得分最差的是普通外科、精神科、妇产科、儿科和重症监护。神经科医生自报健康的年龄组好似跷跷板,30岁到50岁的神经科医生自认为比其他科的医生要健康,40岁和60岁的反而认为自身健康是落后的。
 9、超重吗?
       医生体重要比普通大众控制的好一些,但仍有改善的空间。约32%的神经科医生报告超重,高于其他科医生(33%)。只有4.8%的神经科医生为肥胖,低于总体水平(5.60%)。
10、锻炼频率?
       调查显示,神经科医生锻炼频率要高于美国人平均水平。尽管神经科医生的锻炼频率在随着年龄的增加而提升,但是没有超过医生的平均水平。
11、多从事什么锻炼?
     有氧运动是首选(超过71%)。超过28%的神经学家将负重训练作为第二选择,其次是竞技体育和瑜伽,太极拳等。
12、吸烟吗?
       神经科医生吸烟率比一般医师高,2.7% vs 1.8%.
13、饮酒频率?
        神经科医生饮酒但不放纵:超过半数的一天少于1次,2.9%每天饮2次或以上。
14、个人财务状况?
       调查表明,许多神经科医生也认为自己有经济困难。超过40%的人说没有或很少存款,只有12%的人认为存款绰绰有余,主要是年轻一代的医生在经济上比较困难。80%的半退休的神经科医生认为他们有充足的储蓄。
15、宗教信仰
      近78%的神经科医生有宗教或精神信仰,36%的人积极实践自己的信仰;男女区别不大。
16、如果被告知绝症神经科医生会做什么?
       在这个问题上,神经科医生比较矛盾,约24%的人不确定。约63%的人选择生活质量,约14%的人希望积极治疗。回答具有年龄差异。最年轻组(31~40岁)中,18%会积极治疗,年龄大于61岁的,积极治疗的比例下降到6.7%。年龄越大,不确定性增加,积极治疗比例下降。
17、使用社会化媒体吗?
       随着年龄增加,对社会化媒体的使用率会下降。31~40岁人群中,只有18%的人报告不使用社会化媒体,61岁以上的人达到40%。Facebook是最流行的;LinkedIn,提供专家交流和联系的网络,有20%的人使用。Twitter不是那么流行。
18、本国人和外国人的比例?
       约63%是在美国出生,8%是儿童时来的美国,约29%是成年人来到的美国。亚洲是最常见的来源,约22%;其次是欧洲/加拿大/大洋洲,约16%;非洲约12%,拉丁美洲约6%。   
19、开什么车?
         前5名:丰田(20%),本田(15%),雷克萨斯(5.9%),宝马(7.2%),梅赛德斯 - 奔驰(7%)。
 20、最喜欢的非医疗APP? 
   

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1897924, encodeId=97ce189e92449, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Wed May 30 15:30:00 CST 2012, time=2012-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725412, encodeId=624e1e25412c5, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Aug 03 15:30:00 CST 2012, time=2012-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350929, encodeId=086e1350929a1, content=<a href='/topic/show?id=f5a31596056' target=_blank style='color:#2F92EE;'>#SCAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15960, encryptionId=f5a31596056, topicName=SCAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Apr 12 12:30:00 CST 2012, time=2012-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443644, encodeId=f0da144364420, content=<a href='/topic/show?id=5b78e4414c7' target=_blank style='color:#2F92EE;'>#神经科#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74414, encryptionId=5b78e4414c7, topicName=神经科)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a4e5108341, createdName=12498f1em09(暂无昵称), createdTime=Thu Apr 12 12:30:00 CST 2012, time=2012-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458531, encodeId=69d514585311f, content=<a href='/topic/show?id=6b5511492e2' target=_blank style='color:#2F92EE;'>#Medscape#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11492, encryptionId=6b5511492e2, topicName=Medscape)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4ab6090887, createdName=bnjfx@128.com, createdTime=Thu Apr 12 12:30:00 CST 2012, time=2012-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605674, encodeId=7d9316056e449, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Apr 12 12:30:00 CST 2012, time=2012-04-12, status=1, ipAttribution=)]
    2012-05-30 smlt2008
  2. [GetPortalCommentsPageByObjectIdResponse(id=1897924, encodeId=97ce189e92449, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Wed May 30 15:30:00 CST 2012, time=2012-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725412, encodeId=624e1e25412c5, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Aug 03 15:30:00 CST 2012, time=2012-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350929, encodeId=086e1350929a1, content=<a href='/topic/show?id=f5a31596056' target=_blank style='color:#2F92EE;'>#SCAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15960, encryptionId=f5a31596056, topicName=SCAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Apr 12 12:30:00 CST 2012, time=2012-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443644, encodeId=f0da144364420, content=<a href='/topic/show?id=5b78e4414c7' target=_blank style='color:#2F92EE;'>#神经科#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74414, encryptionId=5b78e4414c7, topicName=神经科)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a4e5108341, createdName=12498f1em09(暂无昵称), createdTime=Thu Apr 12 12:30:00 CST 2012, time=2012-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458531, encodeId=69d514585311f, content=<a href='/topic/show?id=6b5511492e2' target=_blank style='color:#2F92EE;'>#Medscape#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11492, encryptionId=6b5511492e2, topicName=Medscape)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4ab6090887, createdName=bnjfx@128.com, createdTime=Thu Apr 12 12:30:00 CST 2012, time=2012-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605674, encodeId=7d9316056e449, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Apr 12 12:30:00 CST 2012, time=2012-04-12, status=1, ipAttribution=)]
    2012-08-03 feather89
  3. [GetPortalCommentsPageByObjectIdResponse(id=1897924, encodeId=97ce189e92449, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Wed May 30 15:30:00 CST 2012, time=2012-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725412, encodeId=624e1e25412c5, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Aug 03 15:30:00 CST 2012, time=2012-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350929, encodeId=086e1350929a1, content=<a href='/topic/show?id=f5a31596056' target=_blank style='color:#2F92EE;'>#SCAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15960, encryptionId=f5a31596056, topicName=SCAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Apr 12 12:30:00 CST 2012, time=2012-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443644, encodeId=f0da144364420, content=<a href='/topic/show?id=5b78e4414c7' target=_blank style='color:#2F92EE;'>#神经科#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74414, encryptionId=5b78e4414c7, topicName=神经科)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a4e5108341, createdName=12498f1em09(暂无昵称), createdTime=Thu Apr 12 12:30:00 CST 2012, time=2012-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458531, encodeId=69d514585311f, content=<a href='/topic/show?id=6b5511492e2' target=_blank style='color:#2F92EE;'>#Medscape#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11492, encryptionId=6b5511492e2, topicName=Medscape)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4ab6090887, createdName=bnjfx@128.com, createdTime=Thu Apr 12 12:30:00 CST 2012, time=2012-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605674, encodeId=7d9316056e449, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Apr 12 12:30:00 CST 2012, time=2012-04-12, status=1, ipAttribution=)]
    2012-04-12 zhaojie88
  4. [GetPortalCommentsPageByObjectIdResponse(id=1897924, encodeId=97ce189e92449, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Wed May 30 15:30:00 CST 2012, time=2012-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725412, encodeId=624e1e25412c5, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Aug 03 15:30:00 CST 2012, time=2012-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350929, encodeId=086e1350929a1, content=<a href='/topic/show?id=f5a31596056' target=_blank style='color:#2F92EE;'>#SCAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15960, encryptionId=f5a31596056, topicName=SCAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Apr 12 12:30:00 CST 2012, time=2012-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443644, encodeId=f0da144364420, content=<a href='/topic/show?id=5b78e4414c7' target=_blank style='color:#2F92EE;'>#神经科#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74414, encryptionId=5b78e4414c7, topicName=神经科)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a4e5108341, createdName=12498f1em09(暂无昵称), createdTime=Thu Apr 12 12:30:00 CST 2012, time=2012-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458531, encodeId=69d514585311f, content=<a href='/topic/show?id=6b5511492e2' target=_blank style='color:#2F92EE;'>#Medscape#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11492, encryptionId=6b5511492e2, topicName=Medscape)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4ab6090887, createdName=bnjfx@128.com, createdTime=Thu Apr 12 12:30:00 CST 2012, time=2012-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605674, encodeId=7d9316056e449, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Apr 12 12:30:00 CST 2012, time=2012-04-12, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1897924, encodeId=97ce189e92449, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Wed May 30 15:30:00 CST 2012, time=2012-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725412, encodeId=624e1e25412c5, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Aug 03 15:30:00 CST 2012, time=2012-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350929, encodeId=086e1350929a1, content=<a href='/topic/show?id=f5a31596056' target=_blank style='color:#2F92EE;'>#SCAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15960, encryptionId=f5a31596056, topicName=SCAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Apr 12 12:30:00 CST 2012, time=2012-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443644, encodeId=f0da144364420, content=<a href='/topic/show?id=5b78e4414c7' target=_blank style='color:#2F92EE;'>#神经科#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74414, encryptionId=5b78e4414c7, topicName=神经科)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a4e5108341, createdName=12498f1em09(暂无昵称), createdTime=Thu Apr 12 12:30:00 CST 2012, time=2012-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458531, encodeId=69d514585311f, content=<a href='/topic/show?id=6b5511492e2' target=_blank style='color:#2F92EE;'>#Medscape#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11492, encryptionId=6b5511492e2, topicName=Medscape)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4ab6090887, createdName=bnjfx@128.com, createdTime=Thu Apr 12 12:30:00 CST 2012, time=2012-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605674, encodeId=7d9316056e449, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Apr 12 12:30:00 CST 2012, time=2012-04-12, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1897924, encodeId=97ce189e92449, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Wed May 30 15:30:00 CST 2012, time=2012-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725412, encodeId=624e1e25412c5, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Aug 03 15:30:00 CST 2012, time=2012-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350929, encodeId=086e1350929a1, content=<a href='/topic/show?id=f5a31596056' target=_blank style='color:#2F92EE;'>#SCAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15960, encryptionId=f5a31596056, topicName=SCAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Apr 12 12:30:00 CST 2012, time=2012-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443644, encodeId=f0da144364420, content=<a href='/topic/show?id=5b78e4414c7' target=_blank style='color:#2F92EE;'>#神经科#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74414, encryptionId=5b78e4414c7, topicName=神经科)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a4e5108341, createdName=12498f1em09(暂无昵称), createdTime=Thu Apr 12 12:30:00 CST 2012, time=2012-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458531, encodeId=69d514585311f, content=<a href='/topic/show?id=6b5511492e2' target=_blank style='color:#2F92EE;'>#Medscape#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11492, encryptionId=6b5511492e2, topicName=Medscape)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4ab6090887, createdName=bnjfx@128.com, createdTime=Thu Apr 12 12:30:00 CST 2012, time=2012-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605674, encodeId=7d9316056e449, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Apr 12 12:30:00 CST 2012, time=2012-04-12, status=1, ipAttribution=)]

相关资讯

带状疱疹后神经痛治疗进展

       中华医学会麻醉学分会疼痛专业学组秘书长、世界疼痛医师协会中国分会秘书长、航空总医院麻醉与危重医学中心主任兼疼痛医学中心主任,清华大学第二附属医院疼痛医学科安建雄主任经过多年的努力,应用计算机导航辅助技术,对疱疹病毒损伤的神经进行治疗和修复,不仅可以消除自发痛和痛觉过敏等神经病理性疼痛,而且可以恢复长期受损的温度觉和触觉等神经功能,这是迄今可以检

樊东升:高Hcy血症患者卒中预防策略

       脑卒中是目前严重危害人类健康的主要疾病之一。近年来研究发现,血浆中同型半胱氨酸(Hcy)升高与心血管系统疾病、神经系统疾病、糖尿病等多种疾病息息相关。对于脑卒中来说,高Hcy血症是独立危险因素。本文通过对Hcy的代谢途径和相关基因影响的分析,并基于现有的循证医学证据,对高Hcy血症患者的卒中预防策略进行了探讨。   &nbs

华人卒中常见原因:颅内大动脉病变

       据新华网报道,香港中文大学医学院的科学家,通过研究率先证实了颅内大动脉病变是导致华人中风的最常见原因。29日,这个研究成果获得教育部颁发的2011年度“高等学校科学研究优秀成果奖(科学技术)”自然科学奖一等奖。 香港中大医学院黄家星教授        

清华脑起搏器论坛:关注帕金森病

       4月7日,清华大学举办了“清华脑起搏器论坛帕金森病日关爱活动”,由清华大学研制的植入式脑深部刺激器(俗称“脑起搏器”),已在北京天坛医院、北京协和医院完成数十例临床试验,疗效显著。        清华大学副校长程建平指出,随着人口老龄化速度加剧,我

痴呆患者的糖尿病管理,怎样是更合适的选择

       对于合并痴呆的糖尿病患者,适度放松管理似乎更合理,美国老年病学会指南的建议也是如此。毕竟,此类患者的认知障碍使其管理复杂治疗方案的能力降低,并且在发生并发症时,患者存在表述障碍使得与医护人员的沟通难度增加。但在现实临床实践中,是否真的对合并痴呆的糖尿病患者的代谢管理有所放松?多数情况下并非如此,哥伦比亚密苏里大学的Paul Tatum医生说。

2012年大脑意识周:大脑也可以这样艺术

       人们头盖骨内部的粉红色和灰色斑点(blob)并不符合常规的审美观。为了与达纳基金会(The Dana Foundation)和其他组织庆祝2012年3月12日开始的大脑意识周(Brain Awareness Week),Cell Press收集了一些论文:它们重点关注大脑更加艺术性和更加漂亮的方面。     &nb